For many patients living with chronic diseases, treatment often means learning to live with injections. Whether it is managing diabetes, autoimmune disorders, hormone deficiencies, or other serious conditions, millions of people around the world rely on injectable medicines to maintain their health. While these treatments can be highly effective, they also come with challenges. Regular injections can be inconvenient, uncomfortable, and difficult to fit into everyday life.
For decades, scientists have searched for a reliable way to turn these injectable therapies into oral medicines that patients could simply swallow. One company working toward that goal is Biograil, a biotechnology company based in Copenhagen, Denmark. Through its proprietary BIONDD™ technology platform, Biograil is developing a smart drug delivery system designed to enable oral delivery of biologic medicines and other therapeutics that traditionally require injections.
Although the technology is still in development, Biograil has attracted attention from investors and global pharmaceutical companies through its innovative approach to drug delivery. Supported by multiple funding rounds and strategic collaborations, the company is advancing toward clinical testing with the goal of making treatment more convenient for patients in the future.
Biograil Focuses on One of Healthcare’s Most Difficult Problems
Modern medicine has seen remarkable progress in the development of biologic drugs. These therapies, which often contain proteins, peptides, and other complex molecules, have transformed the treatment of many serious diseases. However, one challenge remains difficult to overcome.
Unlike conventional medicines, biologics are generally unable to survive the harsh conditions of the digestive system. Many break down before reaching the bloodstream, while others are absorbed poorly through the gastrointestinal tract. As a result, most biologic therapies must be administered through injections.
This limitation has created a major opportunity for pharmaceutical innovation. Researchers around the world continue to investigate new delivery methods that can provide alternatives to injections while maintaining therapeutic effectiveness. Biograil was established to address this challenge. The company is developing pharmaceutical products based on its BIONDD™ platform, which is designed to facilitate the delivery of active therapeutic compounds through an oral capsule format. The company’s long-term vision is to unlock the potential for oral administration of therapies that currently require injection-based delivery.
How the BIONDD™ Technology Works
At the center of Biograil’s research is the BIONDD™ platform, a proprietary drug delivery technology contained within a standard-sized capsule. Patients take the capsule orally, similar to many common medicines. Once inside the gastrointestinal system, the capsule releases a proprietary delivery device designed to facilitate the administration of therapeutic compounds into the gastrointestinal wall. This approach is intended to help overcome some of the biological barriers that typically prevent biologic medicines from being delivered orally.
According to Biograil, the platform is designed to support the delivery of biologics and other active substances that cannot be effectively absorbed through ordinary tablets or capsules. The company has reported encouraging preclinical findings demonstrating oral delivery of selected compounds using the BIONDD™ platform. These studies have provided important data supporting the continued development of the technology as it moves toward clinical evaluation.
The platform is manufactured using injection molding technology, which provides a scalable manufacturing approach that can support future development and commercialization efforts.
Building a Technology Platform Through Research
Biograil currently operates as a pre-clinical stage biotechnology company. The company’s research efforts focus on validating the safety, functionality, and effectiveness of the BIONDD™ delivery platform before entering human clinical studies. Developing a new drug delivery technology requires years of scientific research, engineering, regulatory preparation, and manufacturing development. Biograil has spent several years advancing these areas while building evidence to support future clinical testing.
The company has stated that preclinical studies have demonstrated promising results for the oral delivery of selected injectable compounds. While additional research and clinical studies are still required, these findings have helped attract interest from both investors and pharmaceutical partners. As healthcare providers continue to seek more patient-friendly treatment options, technologies that can potentially reduce dependence on injections remain an important area of pharmaceutical innovation.
Investors Continue to Support Biograil’s Growth
Biograil’s progress has been supported by several financing rounds that have provided resources for research, development, manufacturing, and regulatory activities. In 2020, the company completed an initial seed financing round valued at approximately €3 million. This funding helped establish the foundation for the continued development of the BIONDD™ platform.
The company later announced the closing of a Seed 2 financing round worth €3.2 million. The round was led by Danish investment company Megatrend Invest and included participation from existing investors Verve Ventures and Sanner Ventures. Evonik Venture Capital joined the investor group as a new participant. The financing was intended to support further development of the technology platform and accelerate progress toward future milestones.
In addition to private investment, Biograil received support from Denmark’s Innobooster program. The non-dilutive grant funding was awarded to assist with preclinical development activities, manufacturing work, and regulatory preparation aimed at advancing the platform toward Phase 1 clinical studies. A significant milestone came in July 2025 when Biograil announced the first closing of an €8.5 million financing round. The round was led by Verve Ventures and included participation from existing investors such as High-Tech Gründerfonds and Megatrend Invest, along with new investor Acondis GmbH.
According to the company, the funding is being used to support planned clinical testing of the BIONDD® oral therapeutic delivery device. The continued financial support reflects investor confidence in the company’s technology and development strategy.
Strategic Partnerships Validate the Platform
Beyond investor support, Biograil has attracted attention from established pharmaceutical companies interested in advancing oral delivery technologies. One of the company’s most notable collaborations involves global pharmaceutical leader Eli Lilly and Company. Biograil announced a Collaboration and License Agreement with Lilly to support the development of oral delivery solutions for therapeutics that are not effectively absorbed through conventional oral dosage forms.
The agreement included research funding, development milestones, royalties, and an equity investment in Biograil. The collaboration represented an important validation of the company’s technology platform and its potential future applications. Biograil expanded its industry relationships further in July 2024 when it announced a collaboration agreement with CSL Behring Lengnau AG, a subsidiary of CSL Limited.
The agreement followed successful early feasibility work and focuses on exploring oral delivery solutions for selected CSL compounds using the BIONDD™ platform. According to Biograil, the collaboration includes research funding, upfront payments, and future licensing options linked to development and commercialization milestones. Partnerships with globally recognized pharmaceutical organizations provide valuable technical expertise and help support the advancement of innovative drug delivery technologies.
CEO Karsten Lindhardt Drives the Company’s Vision
Biograil’s progress has been guided by founder and Chief Executive Officer Karsten Lindhardt, whose educational and professional background combines pharmaceutical science with business leadership. Lindhardt studied business administration and management at Copenhagen Business School and also earned advanced academic qualifications in pharmacology and biopharmacy.
His scientific expertise has played an important role in shaping the company’s research direction and technology strategy. Understanding both pharmaceutical development and business operations has allowed him to guide Biograil through the complex process of building a biotechnology company. As CEO, Lindhardt has overseen multiple funding rounds, helped establish strategic partnerships, and led the advancement of the BIONDD™ platform from concept development toward clinical preparation.
Under his leadership, Biograil has attracted support from international investors, secured collaborations with major pharmaceutical companies, and continued expanding its research capabilities. Lindhardt has consistently emphasized the goal of developing technologies that may help simplify treatment administration for patients while addressing important challenges in biologic drug delivery.
Manufacturing Capabilities Support Future Development
In addition to scientific innovation, Biograil has focused on developing manufacturing processes that can support future growth. The BIONDD™ platform utilizes injection molding technology for device production. This manufacturing approach is widely used across medical and pharmaceutical industries and offers advantages in consistency and scalability.
Building a reliable manufacturing process is a critical step in drug delivery development because regulatory approval requires consistent product quality and performance. Biograil has stated that its platform is designed with manufacturability in mind, helping prepare the technology for future clinical and commercial stages. The company also continues to strengthen its intellectual property position through proprietary technology development and patent-related activities associated with the BIONDD™ platform.
Preparing for the Next Stage of Development
Biograil is now focused on advancing the BIONDD™ platform toward clinical testing. The company remains in the pre-clinical stage, but recent financing and partnership activities have helped position it for future Phase 1 studies. These studies will play a crucial role in evaluating safety and performance in human subjects.
Clinical testing represents one of the most important milestones for any biotechnology company. Positive outcomes can help validate years of research and support progression toward later-stage development.
For Biograil, the coming years will be critical as the company seeks to demonstrate the potential of its oral therapeutic delivery technology through clinical evaluation.
A New Direction for Smart Drug Delivery Systems
The search for effective oral delivery of biologic medicines has challenged scientists for decades. Biograil is among the companies working to address this challenge through innovative drug delivery technology. Its BIONDD™ platform aims to create new possibilities for therapies that currently depend on injections, while maintaining a focus on patient convenience and pharmaceutical innovation.
Supported by verified funding rounds, government-backed development grants, and collaborations with Eli Lilly and CSL Behring, Biograil has established itself as an emerging player in the smart drug delivery field.
While clinical testing and regulatory review still lie ahead, the company continues to advance a technology platform that could contribute to the future evolution of biologic medicine delivery. If successful, Biograil’s work may help expand treatment options and provide a more convenient way for patients to receive important therapies in the years ahead.
